SCHEMBL25211367

SCHEMBL25211367

COC(=O)c1ccnc2[nH]nc(I)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.43
ALDH1A1 P00352 2/20 0.43
GLA P06280 2/20 0.43
GAA P10253 2/20 0.43
MAP2K1 Q02750 1/20 0.42
PSMD14 O00487 1/20 0.40
ATR Q13535 1/20 0.37
TSHR P16473 2/20 0.37
LRRK2 Q5S007 1/20 0.37
NUDT1 P36639 1/20 0.37
POLB P06746 1/20 0.36
ATM Q13315 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
LMNA P02545 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MAPK1 P28482 1/20 0.35
KDM6B O15054 1/20 0.35
KDM5C P41229 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
KDM2A Q9Y2K7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30989273 1.00 KDM4E (0.43) KDM4EALDH1A1GLAGAAMAP2K1
SCHEMBL30989243 0.86 NUDT1 (0.54) KDM4EALDH1A1TSHRNUDT1POLB
SCHEMBL25233792 0.86 NUDT1 (0.54) KDM4EALDH1A1TSHRNUDT1POLB
SCHEMBL29266900 0.83 KDM4E (0.39) KDM4EALDH1A1TSHRTDP1L3MBTL1
SCHEMBL26233951 0.78 PSMD14 (0.45) KDM4EALDH1A1GLAGAAMAP2K1
SCHEMBL19208648 0.76 KDM4E (0.48) KDM4EALDH1A1GAATSHRPOLB
SCHEMBL16341884 0.74 KDM4E (0.46) KDM4EALDH1A1GAATSHRPOLB
SCHEMBL17837494 0.72 LRRK2 (0.34) LRRK2
SCHEMBL26233954 0.72 NR4A2 (0.38) KDM4EALDH1A1GLAGAATSHR
SCHEMBL31632841 0.71 MAP2K1 (0.54) KDM4EALDH1A1GLAGAAMAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250074881-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2025-03-06 US disclosed
US-12110276-B2 Pyrazolo compounds and methods of use thereof GENENTECH, INC. (US) 2024-10-08 US disclosed
EP-4436957-A1 THERAPEUTIC INDAZOLE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER Genentech, Inc. (US) 2024-10-02 EP disclosed
CN-118302411-A Therapeutic indazole compounds and methods of use thereof for the treatment of cancer 基因泰克公司 2024-07-05 CN disclosed
US-20230202984-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2023-06-29 US disclosed
US-20230202984-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2023-06-29 US disclosed
US-20230202984-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2023-06-29 US disclosed
WO-2023097195-A1 THERAPEUTIC INDAZOLE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER GENENTECH, INC. (US) 2023-06-01 WO disclosed
WO-2023097195-A1 THERAPEUTIC INDAZOLE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER GENENTECH, INC. (US) 2023-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074881-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE VHL, TP53, MCL1 KDM4E 2897/4885ALDH1A1 829/4885GLA 555/4885
US-20230202984-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE VHL, TP53, MCL1 KDM4E 2897/4885ALDH1A1 829/4885GLA 555/4885
US-12110276-B2 Pyrazolo compounds and methods of use thereof THPO, KLK3, TP53 KDM4E 2500/4885ALDH1A1 1049/4885GLA 1641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.